Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

This study has been terminated.
Information provided by (Responsible Party):
Biogen Identifier:
First received: December 2, 2008
Last updated: September 17, 2015
Last verified: April 2011
This is a Phase 2, randomized, open-label, multicenter study in subjects with previously untreated CLL. It is designed to evaluate safety and efficacy of fludarabine, cyclophosphamide, rituximab (FCR) and lumiliximab versus FCR alone.

Condition Intervention Phase
Chronic Lymphocytic Leukemia
Drug: Lumiliximab + FCR
Drug: FCR
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Combination With Lumiliximab Versus FCR Alone in Subjects With Previously Untreated Chronic Lymphocytic Leukemia

Resource links provided by NLM:

Further study details as provided by Biogen:

Primary Outcome Measures:
  • To evaluate the safety and tolerability of FCR+L compared with FCR alone in subjects with previously untreated CLL. [ Time Frame: June 2010 ] [ Designated as safety issue: Yes ]
  • To evaluate the efficacy of FCR+L compared with FCR alone in subjects with previously untreated CLL. [ Time Frame: June 2010 ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: February 2008
Study Completion Date: September 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment Group A

FCR + Lumiliximab (L)

L (Lumiliximab): Day 2 50 mg/m2, Day 4 450 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks.

F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks

C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks

R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks

Drug: Lumiliximab + FCR
Dose, schedule, and duration in the protocol
Active Comparator: Treatment Group B


F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks

C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks

R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks

Drug: FCR
Dosage, schedule, and duration in the protocol

Detailed Description:
See protocol.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Age 18 years or older.
  • Previously untreated CD23+ and CD20+ B cell CLL.
  • Life expectancy >6 months.
  • Subjects with Rai Stage III or IV (Binet Stage C) or Rai Stage I or II (Binet Stage A or B) if determined to have active disease.
  • World Health Organization (WHO) Performance Status ≤2.
  • Normal ECG with QTc ≤450 msec for men and ≤460 msec for women. PR interval (Print) must be <240 msec and QRS complex <110 msec. T wave flattening and T wave inversion will be permitted.
  • All male subjects and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 12 months after their last dose of study treatment.
  • Acceptable liver function at Screening.
  • Acceptable hematologic status at Screening.
  • Acceptable renal function at Screening.
  • Subjects receiving any medication known to affect the QTc interval must discontinue the use of the medication or be on a stable dose of the medication for at least 3 months or 5 half-lives (whichever is longer) prior to Study Day 1, and continue (whenever possible) at the same dose throughout the study.


  • Any prior therapy for CLL.
  • Known history or positive test result for human immunodeficiency virus.
  • Known history of, or positive test result for Hepatitis C virus (test for Hepatitis C virus antibody) or Hepatitis B virus (test for Hepatitis B Surface Antigen and Hepatitis B Core Antibody) at Screening.
  • Uncontrolled diabetes mellitus.
  • Uncontrolled hypertension.
  • Hypokalemia.
  • Hypomagnesemia.
  • New York Heart Association Class III or IV cardiac disease; myocardial infarction within the past 6 months prior to Study Day 1.
  • Arrhythmia (other than sinus arrhythmia) within 30 days prior to Study Day 1.
  • Evidence of active myocardial ischemia on ECG.
  • Subjects with pacemakers.
  • Transformation to aggressive B-cell malignancy.
  • Secondary malignancy requiring active treatment.
  • Any medical condition that would require long-term use (>1 month) of systemic corticosteroids during study treatment.
  • Any serious nonmalignant disease or laboratory abnormality, which would confound the evaluation of adverse events (AEs).
  • Active bacterial, viral, or fungal infections.
  • Any known family history of long QT syndrome.
  • Seizure disorders requiring anticonvulsant therapy.
  • Severe chronic obstructive pulmonary disease with hypoxemia.
  • Major surgery, other than diagnostic surgery, within 4 weeks prior to Study Day 1.
  • Clinically active autoimmune disease.
  • Presence of history of Coombs positive hemolytic anemia.
  • Pregnant or currently breastfeeding at Screening.
  • Prior exposure to lumiliximab or any other anti CD23 antibody.
  • Subjects with known hypersensitivity to Chinese hamster ovary cell proteins, murine proteins, or any component of fludarabine, cyclophosphamide, rituximab, or the lumiliximab investigational treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00801060

  Show 36 Study Locations
Sponsors and Collaborators
Study Director: Medical Director Biogen
  More Information

Responsible Party: Biogen Identifier: NCT00801060     History of Changes
Other Study ID Numbers: 152CL202  EUDRACT NO: 2008-002204-25 
Study First Received: December 2, 2008
Last Updated: September 17, 2015
Health Authority: Canada: Ethics Review Committee
Belgium: Federal Agency for Medicinal Products and Health Products
France: Ministry of Health
Austria: Federal Office for Safety in Health Care
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment
United States: Federal Government
Canada: Ministry of Health & Long Term Care, Ontario
France: Haute Autorité de Santé Transparency Commission
Austria: Ethikkommission
France: Institutional Ethical Committee
Australia: Department of Health and Ageing Therapeutic Goods Administration
France: French Data Protection Authority
Canada: Canadian Institutes of Health Research
Austria: Agency for Health and Food Safety
Poland: Ministry of Science and Higher Education
Poland: National Medicines Institute
United Kingdom: Research Ethics Committee
Australia: National Health and Medical Research Council
Poland: Ministry of Health
Belgium: Ministry of Social Affairs, Public Health and the Environment
United Kingdom: National Health Service
Belgium: Institutional Review Board
France: National Consultative Ethics Committee for Health and Life Sciences
Australia: Human Research Ethics Committee
Canada: Health Canada
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United Kingdom: Food Standards Agency
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
United States: Food and Drug Administration
United Kingdom: Department of Health
Belgium: Federal Agency for Medicines and Health Products, FAMHP
France: Direction Générale de la Santé
Austria: Federal Ministry for Health and Women

Keywords provided by Biogen:
Biogen Idec
Chronic Lymphocytic Leukemia

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Fludarabine phosphate
Antibodies, Monoclonal
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Antiviral Agents
Anti-Infective Agents processed this record on December 02, 2016